Platono ir Aristotelio gėrio teorija - 2 psl. Aukštesni žemesni variantai To evaluate the impact of clinical and genetic factors on platelet aggregation of clopidogrel or ticagrelor in patients with aukštesni žemesni variantai coronary syndromes: 1 during induction of antiplatelet therapy and 2 after 4 weeks of antiplatelet therapy; 3 To compare the impact of clinical and genetic factors on platelet aggregation of clopidogrel or ticagrelor during induction aukštesni žemesni variantai after 4 weeks aukštesni žemesni variantai DAPT.
Methods: Platelet aggregation, genotyping and analysis of arachidonic acid metabolites in blood samples were performed for all studied patients. Results: Lower PA values were determined in male patients users of clopidogrel or ticagrelor during induction of antiplatelet therapy after stent implantation.
Higher PA values were determined in clopidogrel treated patients with diabetes during induction variantas aukštesnis žemesnis sužinoti brokerio partijos kainą in ticagrelor treated patients of 65 years old. Significantly lower PA values were observed in smoker users of clopidogrel.
Concomitant amiodarone or metformin use had a significant impact on antiplatelet therapy in clopidogrel or ticagrelor users during induction of antiplatelet therapy.
Significantly higher PA values were determined in concomitant ticagrelor and ACE inhibitor aukštesni žemesni variantai or in clopidogrel and glimepiride users after 4 weeks of induction. Higher 6-trans-leukotriene B4 concentration was observed in clopidogrel but not in ticagrelor treated patients after 4 weeks of treatment.
Conclusions: Patient gender, diabetes, smoking and concomitant use of metformin, amiodarone, ACE inhibitor, and glimepiride have a significant impact on the therapeutic effect of clopidogrel and ticagrelor antiplatelet therapy.
The CYP2C19 variant has a significant effect on platelet reactivity during induction and after 4 weeks in clopidogrel or ticagrelor — treated patients.